{
  "resourceType": "ResearchStudy",
  "id": "ExampleStudyRAAINBOW",
  "meta": {
    "profile": [
      "https://www.vision-zero-oncology.de/fhir/StructureDefinition/clinical-study"
    ]
  },
  "text": {
    "status": "generated",
    "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><b>Generated Narrative</b></p><p><b>identifier</b>: id: NCT03240627</p><p><b>title</b>: Double-blind, Vehicle-controlled, Randomised, Multi-centre Study to Evaluate the Efficacy and Safety of LH-8 Cutaneous Solution in Children and Adolescents With Moderate to Severe Scalp Alopecia Areata.</p><p><b>status</b>: completed</p><p><b>primaryPurposeType</b>: <span title=\"Codes: {http://hl7.org/fhir/R4/valueset-research-study-prim-purp-type.html treatment}\">treatment</span></p><p><b>phase</b>: <span title=\"Codes: {http://terminology.hl7.org/CodeSystem/research-study-phase phase-2-phase-3}\">Phase 2/Phase 3</span></p><p><b>category</b>: <span title=\"Codes: {http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl C98388}\">Interventional Study</span>, <span title=\"Codes: {http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl C46079}\">Randomized Controlled Clinical Trial</span>, <span title=\"Codes: {http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl C15228}\">Double Blind Study</span>, <span title=\"Codes: {http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl C142743}\">Unequal Randomization</span></p><p><b>focus</b>: <span title=\"Codes: {http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl C1909}\">Pharmacologic Substance</span></p><p><b>condition</b>: <span title=\"Codes: {http://snomed.info/sct 68225006}\">Alopecia areata (disorder)</span></p><p><b>location</b>: <span title=\"Codes: {urn:iso:std:iso:3166 DE}\">Germany</span>, <span title=\"Codes: {urn:iso:std:iso:3166 FR}\">France</span></p><p><b>period</b>: 2018-03-01 --&gt; 2022-03-17</p><p><b>principalInvestigator</b>: <a href=\"https://simplifier.net/resolve?scope=de.basisprofil.r4@1.4.0&amp;canonical=http://fhir.org/packages/de.basisprofil.r4/Practitioner/example\">Practitioner/example</a></p><p><b>site</b>: </p><ul><li><a href=\"https://simplifier.net/resolve?scope=de.basisprofil.r4@1.4.0&amp;canonical=http://fhir.org/packages/de.basisprofil.r4/Organization/Charite-dermatology\">Organization/Charite-dermatology</a></li><li><a href=\"https://simplifier.net/resolve?scope=de.basisprofil.r4@1.4.0&amp;canonical=http://fhir.org/packages/de.basisprofil.r4/Organization/Sabouraud-Center\">Organization/Sabouraud-Center</a></li><li><a href=\"https://simplifier.net/resolve?scope=de.basisprofil.r4@1.4.0&amp;canonical=http://fhir.org/packages/de.basisprofil.r4/Organization/Diagnostic-consulting-center-XXIV-Sofia\">Organization/Diagnostic-consulting-center-XXIV-Sofia</a></li><li><a href=\"https://simplifier.net/resolve?scope=de.basisprofil.r4@1.4.0&amp;canonical=http://fhir.org/packages/de.basisprofil.r4/Organization/SC-Centrul-Medical-Sana-SRL\">Organization/SC-Centrul-Medical-Sana-SRL</a></li></ul><blockquote><p><b>arm</b></p><p><b>name</b>: Experimental: LH-8 cutaneous solution</p><p><b>type</b>: <span title=\"Codes: {http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl C174266}\">Investigational Arm</span></p><p><b>description</b>: LH-8 cutaneous solution (0.126 mL per spray) applied to the whole scalp</p></blockquote><blockquote><p><b>arm</b></p><p><b>name</b>: Placebo Comparator: Placebo cutaneous solution</p><p><b>type</b>: <span title=\"Codes: {http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl C174226}\">Control Arm</span></p><p><b>description</b>: Placebo cutaneous solution (0.126 mL per spray) applied to the whole scalp</p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Relative change in scalp alopecia areata severity scores (SALT) from baseline value to be assessed after 24 weeks of treatment. [ Time Frame: 24 weeks treatment ] Visual assessment and global standardised scalp photographs for SALT evaluation.</p><p><b>type</b>: <span title=\"Codes: {http://terminology.hl7.org/CodeSystem/research-study-objective-type primary}\">Primary</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Absolute change in SALT score from baseline at the end of 24 weeks' treatment period. [ Time Frame: 24 weeks treatment ]</p><p><b>type</b>: <span title=\"Codes: {http://terminology.hl7.org/CodeSystem/research-study-objective-type secondary}\">Secondary</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Proportion of the responders, i.e. subjects achieving at least a 40% relative reduction in SALT score from baseline at the end of 24 weeks' treatment period. [ Time Frame: 24 weeks treatment ]</p><p><b>type</b>: <span title=\"Codes: {http://terminology.hl7.org/CodeSystem/research-study-objective-type secondary}\">Secondary</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Adverse events [ Time Frame: 48 weeks ]</p><p><b>type</b>: <span title=\"Codes: {http://terminology.hl7.org/CodeSystem/research-study-objective-type secondary}\">Secondary</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: General physical examination findings, including irritation of eyes and skin [ Time Frame: 24 weeks treatment ]</p><p><b>type</b>: <span title=\"Codes: {http://terminology.hl7.org/CodeSystem/research-study-objective-type secondary}\">Secondary</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Visual assessment and global standardised scalp photographs for SALT evaluation. [ Time Frame: After 12 and 24 weeks treatment ]</p><p><b>type</b>: <span title=\"Codes: {http://terminology.hl7.org/CodeSystem/research-study-objective-type secondary}\">Secondary</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Evaluation of duration of treatment effect in responders, measured as relative SALT score changes from Visit 3 (end of treatment) after 12 weeks (Visit 4) and 24 weeks (Visit 5) of treatment-free period. (Visual assessment and global standardised scalp photographs for SALT evaluation.)</p><p><b>type</b>: <span title=\"Codes: {http://terminology.hl7.org/CodeSystem/research-study-objective-type secondary}\">Secondary</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Assessment of treatment effect on hair follicles in non-alopecic areas by quantifying the number of new alopecic areas. [ Time Frame: 24 weeks treatment ]</p><p><b>type</b>: <span title=\"Codes: {http://terminology.hl7.org/CodeSystem/research-study-objective-type secondary}\">Secondary</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Assessment of the rate of spontaneous hair regrowth. [ Time Frame: For 6-12 months ]</p><p><b>type</b>: <span title=\"Codes: {http://terminology.hl7.org/CodeSystem/research-study-objective-type secondary}\">Secondary</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Assessment of the rate of spontaneous hair regrowth in placebo treated subjects with alopecia areata active for 6-12 months compared to those with alopecia areata active for more than 12 months. (Visual assessment and global standardised scalp photographs for SALT evaluation).</p><p><b>type</b>: <span title=\"Codes: {http://terminology.hl7.org/CodeSystem/research-study-objective-type secondary}\">Secondary</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Absolute and relative change from baseline in Children's Dermatology Life Quality Index (CDLQI) scores. [ Time Frame: 48 weeks ]</p><p><b>type</b>: <span title=\"Codes: {http://terminology.hl7.org/CodeSystem/research-study-objective-type secondary}\">Secondary</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Change in percentage of subjects from baseline by the severity banding CDLQI scores. [ Time Frame: 48 weeks ]</p><p><b>type</b>: <span title=\"Codes: {http://terminology.hl7.org/CodeSystem/research-study-objective-type secondary}\">Secondary</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Percentages of subjects by EuroQol Five Dimensions Youth Questionnaire (EQ-5D-Y) dimensions and levels at Visits 1-5. [ Time Frame: 48 weeks ]</p><p><b>type</b>: <span title=\"Codes: {http://terminology.hl7.org/CodeSystem/research-study-objective-type secondary}\">Secondary</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Absolute and relative change of the EQ-Visual Analogue Scale (EQ-VAS) scores from baseline [ Time Frame: 48 weeks ]</p><p><b>type</b>: <span title=\"Codes: {http://terminology.hl7.org/CodeSystem/research-study-objective-type secondary}\">Secondary</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Evaluation of the Paediatric Alopecia Areata Patient Benefit Index (PAAPBI) scores at Visits 1 to 5. [ Time Frame: 48 weeks ]</p><p><b>type</b>: <span title=\"Codes: {http://terminology.hl7.org/CodeSystem/research-study-objective-type secondary}\">Secondary</span></p></blockquote></div>"
  },
  "identifier": [
    {
      "system": "http://clinicaltrials.gov",
      "value": "NCT03240627"
    }
  ],
  "title": "Double-blind, Vehicle-controlled, Randomised, Multi-centre Study to Evaluate the Efficacy and Safety of LH-8 Cutaneous Solution in Children and Adolescents With Moderate to Severe Scalp Alopecia Areata.",
  "status": "completed",
  "primaryPurposeType": {
    "coding": [
      {
        "system": "http://hl7.org/fhir/R4/valueset-research-study-prim-purp-type.html",
        "code": "treatment"
      }
    ]
  },
  "phase": {
    "coding": [
      {
        "system": "http://terminology.hl7.org/CodeSystem/research-study-phase",
        "code": "phase-2-phase-3",
        "display": "Phase 2/Phase 3"
      }
    ]
  },
  "category": [
    {
      "coding": [
        {
          "system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "code": "C98388",
          "display": "Interventional Study"
        }
      ]
    },
    {
      "coding": [
        {
          "system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "code": "C46079",
          "display": "Randomized Controlled Clinical Trial"
        }
      ]
    },
    {
      "coding": [
        {
          "system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "code": "C15228",
          "display": "Double Blind Study"
        }
      ]
    },
    {
      "coding": [
        {
          "system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "code": "C142743",
          "display": "Unequal Randomization"
        }
      ]
    }
  ],
  "focus": [
    {
      "coding": [
        {
          "system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "code": "C1909",
          "display": "Pharmacologic Substance"
        }
      ]
    }
  ],
  "condition": [
    {
      "coding": [
        {
          "system": "http://snomed.info/sct",
          "code": "68225006",
          "display": "Alopecia areata (disorder)"
        }
      ]
    }
  ],
  "location": [
    {
      "coding": [
        {
          "system": "urn:iso:std:iso:3166",
          "code": "DE",
          "display": "Germany"
        }
      ]
    },
    {
      "coding": [
        {
          "system": "urn:iso:std:iso:3166",
          "code": "FR",
          "display": "France"
        }
      ]
    }
  ],
  "period": {
    "start": "2018-03-01",
    "end": "2022-03-17"
  },
  "principalInvestigator": {
    "reference": "Practitioner/example"
  },
  "site": [
    {
      "reference": "Organization/Charite-dermatology"
    },
    {
      "reference": "Organization/Sabouraud-Center"
    },
    {
      "reference": "Organization/Diagnostic-consulting-center-XXIV-Sofia"
    },
    {
      "reference": "Organization/SC-Centrul-Medical-Sana-SRL"
    }
  ],
  "arm": [
    {
      "name": "Experimental: LH-8 cutaneous solution",
      "type": {
        "coding": [
          {
            "system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "code": "C174266",
            "display": "Investigational Arm"
          }
        ]
      },
      "description": "LH-8 cutaneous solution (0.126 mL per spray) applied to the whole scalp"
    },
    {
      "name": "Placebo Comparator: Placebo cutaneous solution",
      "type": {
        "coding": [
          {
            "system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "code": "C174226",
            "display": "Control Arm"
          }
        ]
      },
      "description": "Placebo cutaneous solution (0.126 mL per spray) applied to the whole scalp"
    }
  ],
  "objective": [
    {
      "name": "Relative change in scalp alopecia areata severity scores (SALT) from baseline value to be assessed after 24 weeks of treatment. [ Time Frame: 24 weeks treatment ] Visual assessment and global standardised scalp photographs for SALT evaluation.",
      "type": {
        "coding": [
          {
            "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type",
            "code": "primary"
          }
        ]
      }
    },
    {
      "name": "Absolute change in SALT score from baseline at the end of 24 weeks' treatment period. [ Time Frame: 24 weeks treatment ]",
      "type": {
        "coding": [
          {
            "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type",
            "code": "secondary"
          }
        ]
      }
    },
    {
      "name": "Proportion of the responders, i.e. subjects achieving at least a 40% relative reduction in SALT score from baseline at the end of 24 weeks' treatment period. [ Time Frame: 24 weeks treatment ]",
      "type": {
        "coding": [
          {
            "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type",
            "code": "secondary"
          }
        ]
      }
    },
    {
      "name": "Adverse events [ Time Frame: 48 weeks ]",
      "type": {
        "coding": [
          {
            "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type",
            "code": "secondary"
          }
        ]
      }
    },
    {
      "name": "General physical examination findings, including irritation of eyes and skin [ Time Frame: 24 weeks treatment ]",
      "type": {
        "coding": [
          {
            "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type",
            "code": "secondary"
          }
        ]
      }
    },
    {
      "name": "Visual assessment and global standardised scalp photographs for SALT evaluation. [ Time Frame: After 12 and 24 weeks treatment ]",
      "type": {
        "coding": [
          {
            "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type",
            "code": "secondary"
          }
        ]
      }
    },
    {
      "name": "Evaluation of duration of treatment effect in responders, measured as relative SALT score changes from Visit 3 (end of treatment) after 12 weeks (Visit 4) and 24 weeks (Visit 5) of treatment-free period. (Visual assessment and global standardised scalp photographs for SALT evaluation.)",
      "type": {
        "coding": [
          {
            "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type",
            "code": "secondary"
          }
        ]
      }
    },
    {
      "name": "Assessment of treatment effect on hair follicles in non-alopecic areas by quantifying the number of new alopecic areas. [ Time Frame: 24 weeks treatment ]",
      "type": {
        "coding": [
          {
            "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type",
            "code": "secondary"
          }
        ]
      }
    },
    {
      "name": "Assessment of the rate of spontaneous hair regrowth. [ Time Frame: For 6-12 months ]",
      "type": {
        "coding": [
          {
            "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type",
            "code": "secondary"
          }
        ]
      }
    },
    {
      "name": "Assessment of the rate of spontaneous hair regrowth in placebo treated subjects with alopecia areata active for 6-12 months compared to those with alopecia areata active for more than 12 months. (Visual assessment and global standardised scalp photographs for SALT evaluation).",
      "type": {
        "coding": [
          {
            "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type",
            "code": "secondary"
          }
        ]
      }
    },
    {
      "name": "Absolute and relative change from baseline in Children's Dermatology Life Quality Index (CDLQI) scores. [ Time Frame: 48 weeks ]",
      "type": {
        "coding": [
          {
            "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type",
            "code": "secondary"
          }
        ]
      }
    },
    {
      "name": "Change in percentage of subjects from baseline by the severity banding CDLQI scores. [ Time Frame: 48 weeks ]",
      "type": {
        "coding": [
          {
            "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type",
            "code": "secondary"
          }
        ]
      }
    },
    {
      "name": "Percentages of subjects by EuroQol Five Dimensions Youth Questionnaire (EQ-5D-Y) dimensions and levels at Visits 1-5. [ Time Frame: 48 weeks ]",
      "type": {
        "coding": [
          {
            "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type",
            "code": "secondary"
          }
        ]
      }
    },
    {
      "name": "Absolute and relative change of the EQ-Visual Analogue Scale (EQ-VAS) scores from baseline [ Time Frame: 48 weeks ]",
      "type": {
        "coding": [
          {
            "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type",
            "code": "secondary"
          }
        ]
      }
    },
    {
      "name": "Evaluation of the Paediatric Alopecia Areata Patient Benefit Index (PAAPBI) scores at Visits 1 to 5. [ Time Frame: 48 weeks ]",
      "type": {
        "coding": [
          {
            "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type",
            "code": "secondary"
          }
        ]
      }
    }
  ]
}